Repros Gives Update on Androxal(R) With Respect to Recent FDA Advisory Panel Outcome and Announces Upcoming Presentation at Biocentury
September 22, 2014 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the conclusions of the FDA Advisory Panel that met on Wednesday, September...
Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism
August 27, 2014 20:10 ET
|
Repros Therapeutics Inc.
23.8% of Topical T subjects below 10 million sperm/mL at end of study versus 2.3% and 2.4% respectively for Androxal® and placebo ITT (Androxal® vs. Topical T, p = 0.0031)
33.3%...
Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results
August 11, 2014 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2014.
Financial Results...
FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel and Placebo
July 16, 2014 09:20 ET
|
Repros Therapeutics Inc.
Schedule for study completion remains unaffected
Company anticipates submission of NDA by year end 2014
THE WOODLANDS, Texas, July 16, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics...
Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel
May 13, 2014 10:15 ET
|
Repros Therapeutics Inc.
Company expects topline results by Q4 2014
Study designed to allow comparison of performance of Androxal® to testosterone replacement in restoring and maintaining normal testicular...
Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results
May 12, 2014 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, May 12, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2014.
Financial Results...
FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel
April 30, 2014 16:01 ET
|
Repros Therapeutics Inc.
Co-primary endpoints of better maintenance of normal sperm concentration and smaller decline in sperm concentration, both compared to topical gel
Company believes the timelines for study...
Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel
April 14, 2014 09:44 ET
|
Repros Therapeutics Inc.
Company expects topline results by October 2014
Studies designed to compare performance of Androxal to testosterone replacement in restoring and maintaining normal testicular function...
Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis
March 17, 2014 09:20 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, March 17, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has received guidance from the FDA indicating that Repros may proceed to conduct...
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results
March 13, 2014 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, March 13, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31,...